Personal tools

Coexpression cluster:C231: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 3: Line 3:
|gostat_on_coexpression_clusters=GO:0008116!prostaglandin-I synthase activity!0.0280230778288002!5740
|gostat_on_coexpression_clusters=GO:0008116!prostaglandin-I synthase activity!0.0280230778288002!5740
|id=C231
|id=C231
|ontology_enrichment_celltype=CL:0000055!3.25e-20!180;CL:0000680!2.49e-16!57;CL:0000056!2.49e-16!57;CL:0000355!2.49e-16!57;CL:0000187!2.36e-15!54;CL:0000183!1.14e-14!59;CL:0000192!5.85e-14!42;CL:0000514!5.85e-14!42;CL:0000393!2.75e-13!60;CL:0000211!2.75e-13!60;CL:0000222!1.12e-12!119;CL:0000359!6.56e-12!32;CL:0000144!7.26e-12!625;CL:0000548!2.80e-11!679;CL:0000004!2.80e-11!679;CL:0000255!2.80e-11!679;CL:0000220!1.09e-10!246;CL:0002321!1.92e-10!248;CL:0000012!2.41e-10!682;CL:0000077!5.52e-09!19;CL:0002494!1.75e-08!16;CL:0002371!6.25e-08!591;CL:0002334!1.01e-07!12;CL:0000057!1.83e-07!75
|ontology_enrichment_disease=DOID:2394!5.78e-09!14;DOID:193!7.82e-07!29
|ontology_enrichment_uberon=UBERON:0001134!3.00e-15!61;UBERON:0002036!3.00e-15!61;UBERON:0003082!3.00e-15!61;UBERON:0002385!8.01e-15!63;UBERON:0001015!8.01e-15!63;UBERON:0000383!8.01e-15!63;UBERON:0004290!8.15e-12!70;UBERON:0004872!2.28e-11!84;UBERON:0000914!6.53e-11!83;UBERON:0002329!6.53e-11!83;UBERON:0003077!6.53e-11!83;UBERON:0003059!6.53e-11!83;UBERON:0007282!6.53e-11!83;UBERON:0009618!6.53e-11!83;UBERON:0007285!6.53e-11!83;UBERON:0001637!7.09e-11!42;UBERON:0003509!7.09e-11!42;UBERON:0004572!7.09e-11!42;UBERON:0000486!9.12e-11!82;UBERON:0000926!2.19e-10!448;UBERON:0004120!2.19e-10!448;UBERON:0006603!2.19e-10!448;UBERON:0002204!1.34e-09!167;UBERON:0004573!2.19e-09!33;UBERON:0004571!2.19e-09!33;UBERON:0000490!3.19e-09!138;UBERON:0000468!3.52e-09!659;UBERON:0000948!3.58e-09!24;UBERON:0005498!3.58e-09!24;UBERON:0004140!3.58e-09!24;UBERON:0009881!3.58e-09!24;UBERON:0004141!3.58e-09!24;UBERON:0003084!3.58e-09!24;UBERON:0007005!3.58e-09!24;UBERON:0004139!3.58e-09!24;UBERON:0004291!3.58e-09!24;UBERON:0005256!6.42e-09!143;UBERON:0000467!1.03e-08!625;UBERON:0003914!1.23e-08!118;UBERON:0007100!1.39e-08!27;UBERON:0000480!1.49e-08!626;UBERON:0001981!7.03e-08!60;UBERON:0007500!7.03e-08!60;UBERON:0004537!7.03e-08!60;UBERON:0006965!7.03e-08!60;UBERON:0002049!1.22e-07!79;UBERON:0007798!1.22e-07!79;UBERON:0004535!1.46e-07!110;UBERON:0001009!1.56e-07!113
}}
}}

Revision as of 14:22, 21 May 2012


Full id: C231_Mesothelial_mesenchymal_mesothelioma_Fibroblast_Preadipocyte_leiomyoma_mycosis



Phase1 CAGE Peaks

Hg19::chr10:29248821..29248844,-p@chr10:29248821..29248844
-
Hg19::chr10:29248873..29248901,-p@chr10:29248873..29248901
-
Hg19::chr11:111724419..111724469,-p@chr11:111724419..111724469
-
Hg19::chr11:111724532..111724542,-p@chr11:111724532..111724542
-
Hg19::chr11:111724543..111724555,-p@chr11:111724543..111724555
-
Hg19::chr11:127841493..127841504,-p@chr11:127841493..127841504
-
Hg19::chr11:127875726..127875731,-p@chr11:127875726..127875731
-
Hg19::chr12:120502376..120502385,+p8@CCDC64
Hg19::chr12:120502386..120502408,+p1@CCDC64
Hg19::chr13:108074395..108074398,-p@chr13:108074395..108074398
-
Hg19::chr13:38083829..38083838,+p@chr13:38083829..38083838
+
Hg19::chr13:38083855..38083873,+p@chr13:38083855..38083873
+
Hg19::chr13:38143481..38143491,-p@chr13:38143481..38143491
-
Hg19::chr13:38143907..38143931,+p@chr13:38143907..38143931
+
Hg19::chr13:38144712..38144754,+p@chr13:38144712..38144754
+
Hg19::chr14:45251913..45251924,-p2@ENST00000556405
Hg19::chr14:45251956..45251976,-p1@ENST00000556405
Hg19::chr14:45252031..45252036,-p5@ENST00000556405
Hg19::chr14:45252056..45252063,-p4@ENST00000556405
Hg19::chr14:45252105..45252117,-p3@ENST00000556405
Hg19::chr15:101445820..101445832,-p@chr15:101445820..101445832
-
Hg19::chr15:63449025..63449064,-p3@RPS27L
Hg19::chr15:63450169..63450189,-p5@RPS27L
Hg19::chr15:63450192..63450226,-p2@RPS27L
Hg19::chr15:63536192..63536195,+p@chr15:63536192..63536195
+
Hg19::chr17:38128375..38128405,+p@chr17:38128375..38128405
+
Hg19::chr17:67031950..67031959,-p5@ABCA9
Hg19::chr18:20419512..20419521,-p@chr18:20419512..20419521
-
Hg19::chr18:7813360..7813367,+p@chr18:7813360..7813367
+
Hg19::chr19:10687907..10687918,-p@chr19:10687907..10687918
-
Hg19::chr1:22745420..22745427,-p@chr1:22745420..22745427
-
Hg19::chr1:22745449..22745465,-p@chr1:22745449..22745465
-
Hg19::chr1:22745469..22745477,-p@chr1:22745469..22745477
-
Hg19::chr1:59522284..59522317,+p@chr1:59522284..59522317
+
Hg19::chr1:64686211..64686219,+p@chr1:64686211..64686219
+
Hg19::chr20:1435971..1435982,-p@chr20:1435971..1435982
-
Hg19::chr20:48184518..48184520,-p@chr20:48184518..48184520
-
Hg19::chr20:48184812..48184818,-p13@PTGIS
Hg19::chr22:37633537..37633546,-p@chr22:37633537..37633546
-
Hg19::chr2:135168644..135168657,+p@chr2:135168644..135168657
+
Hg19::chr2:135168804..135168814,+p@chr2:135168804..135168814
+
Hg19::chr2:151742292..151742317,+p@chr2:151742292..151742317
+
Hg19::chr2:220309507..220309512,+p33@SPEG
Hg19::chr2:25326312..25326322,+p@chr2:25326312..25326322
+
Hg19::chr3:8989081..8989115,-p@chr3:8989081..8989115
-
Hg19::chr4:142141683..142141694,+p3@ZNF330
Hg19::chr4:28801404..28801410,-p@chr4:28801404..28801410
-
Hg19::chr4:38119558..38119577,+p@chr4:38119558..38119577
+
Hg19::chr5:149682252..149682265,-p6@ARSI
Hg19::chr5:149682332..149682346,-p3@ARSI
Hg19::chr6:159309490..159309509,+p10@C6orf99
Hg19::chr7:43584118..43584127,-p@chr7:43584118..43584127
-
Hg19::chr8:117463964..117463997,-p@chr8:117463964..117463997
-
Hg19::chr8:125754675..125754679,-p@chr8:125754675..125754679
-
Hg19::chr8:74498501..74498510,-p@chr8:74498501..74498510
-
Hg19::chr9:113208581..113208593,-p@chr9:113208581..113208593
-
Hg19::chr9:118053068..118053087,+p1@DEC1
Hg19::chr9:16727001..16727016,+p@chr9:16727001..16727016
+
Hg19::chr9:33185050..33185064,-p@chr9:33185050..33185064
-
Hg19::chr9:33185073..33185094,-p@chr9:33185073..33185094
-
Hg19::chr9:35027511..35027519,-p@chr9:35027511..35027519
-


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

GO IDGO nameFDR corrected p-value
GO:0008116prostaglandin-I synthase activity0.0280230778288002



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>

Uber Anatomy
Ontology termp-valuen
skeletal muscle tissue3.00e-1561
striated muscle tissue3.00e-1561
myotome3.00e-1561
muscle tissue8.01e-1563
musculature8.01e-1563
musculature of body8.01e-1563
dermomyotome8.15e-1270
splanchnic layer of lateral plate mesoderm2.28e-1184
somite6.53e-1183
paraxial mesoderm6.53e-1183
presomitic mesoderm6.53e-1183
presumptive segmental plate6.53e-1183
trunk paraxial mesoderm6.53e-1183
presumptive paraxial mesoderm6.53e-1183
artery7.09e-1142
arterial blood vessel7.09e-1142
arterial system7.09e-1142
multilaminar epithelium9.12e-1182
mesoderm2.19e-10448
mesoderm-derived structure2.19e-10448
presumptive mesoderm2.19e-10448
musculoskeletal system1.34e-09167
systemic artery2.19e-0933
systemic arterial system2.19e-0933
unilaminar epithelium3.19e-09138
multi-cellular organism3.52e-09659
heart3.58e-0924
primitive heart tube3.58e-0924
primary heart field3.58e-0924
anterior lateral plate mesoderm3.58e-0924
heart tube3.58e-0924
heart primordium3.58e-0924
cardiac mesoderm3.58e-0924
cardiogenic plate3.58e-0924
heart rudiment3.58e-0924
trunk mesenchyme6.42e-09143
anatomical system1.03e-08625
epithelial tube1.23e-08118
primary circulatory organ1.39e-0827
anatomical group1.49e-08626
blood vessel7.03e-0860
epithelial tube open at both ends7.03e-0860
blood vasculature7.03e-0860
vascular cord7.03e-0860
vasculature1.22e-0779
vascular system1.22e-0779
cardiovascular system1.46e-07110
circulatory system1.56e-07113
Disease
Ontology termp-valuen
ovarian cancer5.78e-0914
reproductive organ cancer7.82e-0729


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=Coexpression_cluster:C231&oldid=1705052"